MedTrace Logo

Tissue K+ in Primary Hyperaldosteronism

NCT04251780 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2025-11-25

No results posted yet for this study

Summary

Recent human studies found tissue sodium storage in patients with hyperaldosteronism that could be detected non-invasively by 23Na-MRI. Tissue sodium accumulation could be mobilized upon treatment of hyperaldosteronism. Besides, former animal studies applying chemical electrolyte analysis indicate that this aldosterone induced sodium storage might be accompanied by intracellular potassium loss. Wether such an intracellular tissue potassium loss occurs in vivo in patients with hyperaldosteronism and if this deficiency can be corrected by treatment is unclear. The investigators will employ 39K-MR Imaging at 7Tesla to further assess this hypothesis.

Conditions

  • Primary Hyperaldosteronism
  • Electrolyte Disturbance

Interventions

PROCEDURE

Surgical Treatment of Primary Aldosteronism

Surgery of an unilateral adrenal disease

DRUG

Drug treatment of Primary Aldosteronism

Treatment of Primary Aldosteronism with Spironolactone or Eplerenone.

Sponsors & Collaborators

  • University of Erlangen-Nürnberg Medical School

    lead OTHER

Principal Investigators

  • Christoph Kopp, MD · Nephrology Department, University Erlangen-Nurnberg, Germany

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2024-04-24
Completion
2024-04-24

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04251780 on ClinicalTrials.gov